Advanced in Lynch Syndrome

Dr. Jamie N. Bakkum-Gamez

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
200 1st St Sw, 
Rochester, MN 
Accepting New Patients
Offers Telehealth
Advanced in Lynch Syndrome
200 1st St Sw, 
Rochester, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jamie Bakkum-Gamez is a Gynecologic Oncologist and an Oncologist in Rochester, Minnesota. Dr. Bakkum-Gamez is rated as an Advanced provider by MediFind in the treatment of Lynch Syndrome. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Vulvar Cancer, Hysterectomy, and Tubal Ligation. Dr. Bakkum-Gamez is currently accepting new patients.

Her clinical research consists of co-authoring 181 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Lynch Syndrome.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in MN
Hospital Affiliations
Mayo Clinic Hospital Rochester
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

MAYO CLINIC
200 1st St Sw, Rochester, MN 55905

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer
Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2026
Intervention Type: Procedure, Drug, Biological, Other
Study Phase: Phase 1
WISP (Women Choosing Surgical Prevention)
WISP (Women Choosing Surgical Prevention)
Enrollment Status: Active_not_recruiting
Publish Date: January 07, 2026
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

182 Total Publications

Early introduction of trastuzumab deruxtecan (T-DXd) in HER2 expressing rare gynecologic malignancies - How early is too early?
Early introduction of trastuzumab deruxtecan (T-DXd) in HER2 expressing rare gynecologic malignancies - How early is too early?
Journal: Gynecologic oncology reports
Published: October 31, 2025
Similar Doctors
Distinguished in Lynch Syndrome
Dr. Katrina Pedersen
Hematology | Oncology
Distinguished in Lynch Syndrome
Dr. Katrina Pedersen
Hematology | Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Katrina Pedersen is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Pedersen has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Lynch Syndrome. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, and Familial Pancreatic Cancer.

Distinguished in Lynch Syndrome
Dr. Zhaohui Jin
Hematology | Oncology
Distinguished in Lynch Syndrome
Dr. Zhaohui Jin
Hematology | Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances

Zhaohui Jin is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Jin is rated as a Distinguished provider by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, Pancreatic Cancer, and Pancreaticoduodenectomy.

Distinguished in Lynch Syndrome
Dr. David Marinier
Hematology | Oncology
Distinguished in Lynch Syndrome
Dr. David Marinier
Hematology | Oncology

Gundersen Clinic Ltd

123 Se 5th Ave, 
Spring Grove, MN 
 (52.6 miles away)
507-498-3302
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Marinier is a Hematologist and an Oncologist in Spring Grove, Minnesota. Dr. Marinier is rated as a Distinguished provider by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Colorectal Cancer, and Lynch Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bakkum-Gamez's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 11 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile